<DOC>
	<DOCNO>NCT01929863</DOCNO>
	<brief_summary>Metformin may complex interaction gut generally first line therapy type 2 diabetes mellitus ( T2DM ) . It important understand whether significant pharmacokinetic pharmacodynamic interaction GSK2330672 co-administered metformin subject T2DM . The purpose study investigate safety tolerability GSK2330672 administer 7 day subject T2DM take metformin . This two-period crossover study ; subject receive either GSK2330672 placebo 7 day period separate washout period 13 15 day . All subject receive metformin throughout study</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics GSK2330672 Type 2 Diabetes Patients Taking Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Males female age 30 64 year age inclusive , time signing informed consent . Subjects document T2DM diagnosis ( diagnose less 3 month prior screen ) ; AND one following : take stable metformin 850 milligram ( mg ) twice daily ( BID ) ( equivalent 1700 mg/day ) least 4 week prior screen glycosolated haemoglobin A1c ( HbA1c ) &gt; =7.0 % &lt; =11 % screening ; OR take stable metformin &gt; =1000 mg/day &lt; 1700 mg/day least 4 week prior screen HbA1c &gt; =7.5 % &lt; =11 % Screening ; OR take stable metformin &gt; 1700 &lt; =2000 mg/day least 4 week prior screen HbA1c &gt; =7.0 % &lt; =10 % screening ; take antidiabetic medication . All T2DM subject must meet label recommendation metformin , include : Adequate renal function , evidence Modification Diet Renal Disease estimate glomerular filtration rate &gt; =60 milliliter ( mL ) /minute ( min ) ; No condition make hypoxia , dehydration , sepsis likely ; No clinical laboratory evidence hepatic disease ( include history cholecystitis symptomatic gallstone ) cardiac disease ( include history myocardial infarction heart failure ) . Subjects history cholelithiasis uncomplicated cholecystectomy 3 month screen may eligible approved GlaxoSmithKline ( GSK ) Medical Monitor ; No excessive alcohol intake . Cpeptide &gt; 0.8 nanogram ( ng ) /mL screen visit . Urine albumintocreatinine ratio &lt; 30 mg/gram ( g ) . Fasting plasma glucose &lt; 280 mg/decilitre ( dL ) Body mass index ( BMI ) 24 40 kilogram ( kg ) /square meter ( m^2 ) , inclusive In good general health ( opinion investigator ) clinically significant relevant abnormality medical history physical examination would introduce additional risk factor interfere study procedure objective , base medical evaluation include medical history , physical examination , vital sign laboratory test . Female subject nonchildbearing potential . Nonchildbearing potential define : Premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] . Postmenopausal define 12 month spontaneous amenorrhea . In questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit ( MIU ) /mL estradiol &lt; 40 picograms ( pg ) /mL ( &lt; 147 picomole [ pmol ] /liter [ L ] ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one acceptable contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Male subject female partner childbearing potential must agree use one acceptable contraception method . This criterion must follow time first dose study medication follow visit . Capable give write informed consent , include compliance requirement restriction list consent form CRITERIA BASED UPON MEDICAL HISTORIES : Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome ) . History chronic acute pancreatitis . Approval GSK Medical Monitor must obtain subject past history pancreatitis 12 month start treatment period ( subject history pancreatitis within 12 month prior start treatment period exclude ) . History gastrointestinal ( GI ) disease ( e.g. , irritable bowel disease , chronic current diarrhea , inflame bowel , steatorrhoea/fat malabsorption , celiac disease , symptomatic lactose intolerance ) . Subjects gastroparesis require treatment exclude . History significant cardiovascular disease include acute myocardial infarction , stroke , hospitalization acute coronary syndrome , heart failure within previous 12 month . Uncontrolled hypertension , evidence systolic pressure &gt; 160 diastolic pressure &gt; 90 . Subjects take antihypertensive medication permit . Significant ECG abnormality , define follow : Heart rate ( rest ) &lt; 50 &gt; 100 beat per minute ( bpm ) ; PR Interval &lt; 120 &gt; 220 millisecond ( msec ) ; QRS duration &lt; 70 &gt; 120 msec History untreated pernicious anemia laboratory parameter suggestive subclinical megaloblastic anemia ( e.g. , increased mean corpuscular volume low red blood cell count and/or haemoglobin level ) . Current relevant previous significant medical disorder may require treatment make subject unlikely fully complete study , condition , opinion investigator , present undue risk study medication procedure . Thyroid Disease : Uncorrected Thyroid Dysfunction : Fasting plasma thyroid stimulate hormone ( TSH ) outside normal range , determine screening visit ; Subjects stable thyroid replacement therapy TSH normal range eligible approve GSK Medical Monitor ; Unevaluated thyroid nodule goiter Screening . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation CRITERIA BASED UPON DIAGNOSTIC ASSESSMENTS : Alanine transaminase , alkaline phosphatase bilirubin &gt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based average QTcF value triplicate ECGs obtain least 1 minute apart within approximately 15 minute : QTcF &gt; =450 msec ; QTcF &gt; =480 msec subject Bundle Branch Block ( subject leave bundle branch block exclude ) A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test human immunodeficiency virus antibody A positive prestudy drug/alcohol urine screen A subject positive urine cotinine test result exclude study unless judgment Investigator subject able abstain use tobacco duration inhouse period study . OTHER CRITERIA Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . A subject fasting plasma glucose Day 1 100 mg/dL low screen must randomize , unless repeat test value le 100 mg/dL screen value .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Diabetes</keyword>
</DOC>